The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

Oprah Winfrey reflects on past misconceptions about weight, admitting that a GLP-1 drug shifted her perspective.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...